Financial Consulate’s Candel Therapeutics CADL Stock Holding History

Financial Consulate’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.71K	Buy	+164	New	+$1.82K	﹤0.01%	1158

Other funds holding CADL

Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Financial Consulate's CADL Position: Q3 2026 in Review

Financial Consulate opened a new position in Candel Therapeutics (CADL) in Q3 2026: 164 shares worth $1.71K. The stake represents ﹤0.01% of the portfolio and ranks #1158 among its holdings.

12 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

Financial Consulate held 164 shares of Candel Therapeutics worth $1.71K as of Q3 2026.
Candel Therapeutics was a new Financial Consulate position in Q3 2026.
Candel Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1158 holding.
12 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.